Covidien (NYSE:COV) hit a new 52-week high Thursday as it changed hands at $52.49 compared with its previous 52-week high of $52.48. Covidien is currently trading at $52.48 with 1.7 million shares changing hands as of 11:26 a.m..
NEW YORK ( TheStreet) -- Covidien (NYSE: COV) hit a new 52-week high Thursday as it traded at $52.49 compared with its previous 52-Week high of $52.48. Covidien is changing hands at $52.48 with 1.7 million shares traded as of 11:26 a.m. ET. Average volume has been 5.5 million shares over the past 30 days. Covidien has a market cap of $25.4 billion and is part of the health care sector and health services industry. Shares are up 12.6% year to date as of the close of trading on Wednesday. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings in the United States and internationally. The company has a P/E ratio of 16.2, above the average health services industry P/E ratio of 15.7 and below the S&P 500 P/E ratio of 21.5. TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, attractive valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Covidien Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.